Breakthrough vaccine to treat chemo-resistant ovarian cancer

March 8, 2007

Cancer Treatment Centers of America announced today its plans to launch a new cancer vaccine therapy that expands treatment options for thousands of women with advanced stage ovarian cancer. This innovative treatment will be offered by Cancer Treatment Centers of America and developed by AVAX Technologies, Inc.

"Cancer Treatment Centers of America's number one priority is to help our patients win the battle against cancer," said Dr. Edgar Staren, Chief Medical Officer of Cancer Treatment Centers of America. "This vaccine therapy represents a promising new chapter in the fight against this devastating disease and brings hope to women everywhere."

The breakthrough treatment method uses the patient's own tumor tissues to create a patient-specific vaccine and is combined with chemotherapy delivered directly into the abdominal cavity.

Ovarian cancer, one of the hardest cancers to detect in the early stages, is a very complex disease that is often resistant to chemotherapy. Cancer Treatment Centers of America will offer this new treatment to patients whose cancer has recurred after chemotherapy.

"To win the fight against cancer, it is absolutely vital we do everything we can to make innovative new treatments like this available to patients as soon as possible," said Dr. Staren. It's inconceivable that treatments like these – that give hope to patients – are often left on the laboratory bench, while cancer patients are told there is nothing more that can be done for them."

Cancer Treatment Centers of America expects to start treating patients this summer. This promising vaccine technology hopes to eventually be available to treat other forms of cancer including colorectal and lung cancer patients, as well as patients with malignant melanomas.

Source: Cancer Treatment Center of America

Explore further: Medical scientists discover potent method for improving drug-free fertility treatment

Related Stories

Pudendal nerve entrapment can lead to eating disorder

August 23, 2016

(HealthDay)—Pudendal nerve entrapment (PNE) leading to avoidant/restrictive food intake disorder (ARFID) has been described in a case report published online Aug. 19 in the International Journal of Eating Disorders.

Teen survives rare amoeba infection that kills most people

August 23, 2016

A South Florida boy has survived a rare brain-eating amoeba that kills most people, aided in part because a hard-to-get drug to fight the infection is made by a company in Orlando where he was hospitalized, doctors said Tuesday.

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Cow embryos reveal new type of chromosome chimera

May 27, 2016

I've often wondered what happens between the time an egg is fertilized and the time the ball of cells that it becomes nestles into the uterine lining. It's a period that we know very little about, a black box of developmental ...

Shaving time to test antidotes for nerve agents

February 29, 2016

Imagine you wanted to know how much energy it took to bike up a mountain, but couldn't finish the ride to the peak yourself. So, to get the total energy required, you and a team of friends strap energy meters to your bikes ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.